SEC Comment Letter 0000000000-24-000179 to Processa Pharmaceuticals, Inc. (PCSA)
Processa Pharmaceuticals, Inc.
Date: Jan. 5, 2024 · CIK: 0001533743 · Accession: 0000000000-24-000179
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-276308
Letter
United States securities and exchange commission logo January 5, 2024 George Ng Chief Executive Officer Processa Pharmaceuticals, Inc. 7380 Coca Cola Drive, Suite 106 Hanover, MD 21076 Processa Pharmaceuticals, Inc. Re:Processa Pharmaceuticals, Inc. Registration Statement on Form S-1 Filed December 29, 2023 File No. 333-276308 Dear George Ng: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Jason Drory at 202-551-8342 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Michael Kirwan
Show Raw Text
United States securities and exchange commission logo
January 5, 2024
George Ng
Chief Executive Officer
Processa Pharmaceuticals, Inc.
7380 Coca Cola Drive, Suite 106
Hanover, MD 21076
Processa Pharmaceuticals, Inc.
Re:Processa Pharmaceuticals, Inc.
Registration Statement on Form S-1
Filed December 29, 2023
File No. 333-276308
Dear George Ng:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Jason Drory at 202-551-8342 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Michael Kirwan